Next Phase Newsletter

A venture capital firm invests primarily in very early-stage companies, from pre-seed to seed stages. The firm’s average check size ranges from $250,000 to $500,000. While the firm is focused on the US, particularly in the West Coast, it remains open to global opportunities. The firm is flexible in both lending and co-investing and may seek an observer seat on a case-by-case basis. The firm plays an active role in supporting its portfolio companies, assisting them with concept validation, clinical trials, and navigating reimbursement and regulatory pathways. The firm also provides resources to help companies gather data and evidence for their minimum viable products. 
 
The firm is interested in opportunities across digital therapeutics, diagnostics, and medical devices. Some key indication areas of interest include cardiovascular, metabolic, diabetes, nephropathy, and women’s health. The firm typically focuses on less traditional pharma products, such as compounds and cell-based therapies. The firm prefers to engage with companies at an early stage and will consider those with at least a minimum viable product. 
 
The firm does not have specific requirements for a company’s founding team. However, the firm prefers companies based in the U.S. or those with incentives to relocate to the U.S. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A global corporation and integrated business enterprise is interested in expanding the healthcare business and increasing its presence in the US. The firm seeks to make engage with early and mid-stage healthcare companies through strategic investment, partnerships, and more. The firm is open to global opportunities. 
 
Within life sciences and healthcare sectors, the firm is most interested in medical devices, diagnostics, digital health, and healthcare services. Within medtech, the firm focuses on surgical applications, respiratory/anesthesia, radiology, cardiology, etc. In digital health, technologies addressing areas such as virtual care providers, wellness management, etc. that could benefit the aging population are of interest. The firm is can partner with companies across a wide stage of development, from companies still developing a prototype to those who are already on the market. The firm does not invest in biotech or pharmaceutical companies. 
 
The firm has no specific company or management team requirements. The firm is interested in companies who are looking to enter the Asian market, and can help support the companies in navigating regulatory hurdles by leveraging their own regulatory team. The firm can act as a lead or co-investor. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A boutique venture capital firm manages an evergreen USD fund. The fund focuses on healthcare industry, generally participating in Series A or B rounds but would also consider seed and growth-stage funding. Typical equity investment size ranges from $3-5M. The firm is open to both leading and co-investing. The firm is actively seeking new opportunities from across the world with a focus on companies in China, U.S., Europe, and Israel. The firm helps portfolio companies get into massive and fast-growing markets of China and Asia, and assists Chinese companies to expand abroad. 
 
The firm is most interested in biopharma, biotechnology, medical devices, artificial intelligence. Within medtech, the firm is seeking post-prototype innovations that are FDA cleared or are close to receiving clearance. Within therapeutics, the firm is interested in therapeutics for large disease markets such as oncology, neurology, and metabolic diseases. The firm is open to all modalities with a special interest in immunotherapy and cell therapy. 
 
The firm is in search of ambitious companies with strong, experienced management teams. The firm takes a hands-on approach to portfolio companies and can work with incomplete teams. The firm can contribute expertise in essential services: branding, marketing, channel development, overseas expansion, human resources and finance. 
 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm headquartered in the US is dedicated to advancing healthier outcomes for all by partnering with technology-powered innovators. The team consists of industry-seasoned leaders with deep health-tech experience. The firm will invest in Seed – Series B rounds, with a sweet spot for Series A. The firm makes initial equity investments of $3M-$10M and typically leads rounds. The firm will invest globally. 
 
The firm invests in healthcare software, services, and solutions based digital health companies. 
 
The firm has no strict team requirements. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A private investment vehicle established recently and headquartered in Asia is mainly interested in investing in global healthcare companies, co-investing in Pre-Seed up to Series A rounds. Currently, they have five portfolio companies spanning biotech, digital health, and medical devices. Initial check size is flexible, but the firm will allocate up to USD $400k up to Seed rounds and USD $1-2M up to Series A. 
 
The firm is open to biotech, first-in-class drugs, medical devices, digital health, and diagnostics. Though indication and technology-agnostic, next generation and innovative technologies are of interest. 
 
The firm does not have strict company or management team requirements. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A public company based in China has its core businesses in-vitro diagnostics and radiation therapy. The corporate fund of this company is looking to work with early-stage medical device companies using a variety of structures, including equity investments and M&A. The firm is looking to engage in Seed to Series B/C and the average check size is usually less than 10M USD. The firm is open to opportunities worldwide and prefers companies with some sort of China angles. The firm is looking to make 3-4 new investments within the next 12 months. 
 
While the firm’s core business is in IVD and radiation therapy, the firm is interested in medical devices of all classes. 
 
The firm does not have any specific requirements for the company’s management team, but they do prefer companies with a China angle. The firm is open to both leading and co-investing and is likely to take a board seat when leading. The firm looks to be an active investor and strategically collaborate with their portfolio companies to create synergies. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A joint venture founded between a family office and a holding company is interested in Series A and B medical device companies in the U.S. and Western Europe that are near FDA approval. The firm is also open to Korean and Japanese companies. Typical check sizes range between USD $500k-1.5M, preferring to lead transactions. The firm will also co-invest with the family office’s other investment vehicles to secure right in late-stage revenue-generating companies with a clear path to exit within an 18-24 month time frame. 
 
The firm is interested open to all classes of medical devices, but mainly focuses on human implants. Their core focus is in the neuromuscular space, including orthopedics and spine implants. They are also interested in cardiology, vascular devices, surgical devices, oncology biopharma. Currently, they are looking to expand their core area and look at more cardiovascular, arterial and peripheral devices. Companies should be near FDA approval with proven technology. 
 
The firm requires to take a board seat, observer at minimum. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.